Home-Use Microneedle in the Treatment of Pattern Hair Loss: Efficacy and Safety

In this triple-blind randomized clinical trial, researchers found that oral minoxidil 0.25 mg tablets were as effective as 2% topical minoxidil for increasing hair diameter and density in women with female pattern hair loss, with similarly minor side effects.

This study found that low-dose oral minoxidil 5 mg daily significantly increased hair growth in men with androgenetic alopecia over 24 weeks, with increased hair count and vertex area improvement, though most experienced hypertrichosis and some had pedal edema.

In this study, microneedling with a depth of 0.6 mm, alongside minoxidil, significantly improved hair count and thickness in patients with androgenetic alopecia compared to minoxidil alone, and was more beneficial than a 1.2 mm depth.

In this study, a home-use microneedle device combined with 5% minoxidil showed potential for enhancing hair growth in pattern hair loss over six months, although the observed improvements in hair count and patient assessments were not statistically significant compared to other treatments.

This study reported that combined oral finasteride and topical 5% minoxidil treatment in men with male-pattern hair loss improved hair growth by initiating anagen in pre-existing but deficient follicles, yet the growth rates remained unchanged and did not normalize hair productivity.

In this study, mesotherapy containing nutritional supplements was found to increase patient satisfaction and improve the number of hair follicles more effectively than topical minoxidil in treating female pattern hair loss, though both methods showed similar overall efficacy in hair density and hair loss reduction.

This article discusses treatments for male pattern alopecia, noting variable response rates, but reports no new clinical results.

This study found that combining microneedling with topical minoxidil was more effective than minoxidil alone in increasing hair count and improving patient satisfaction for men with androgenetic alopecia, though the cosmetic impact was not significant.

This study found that combining microneedle treatments with 5% minoxidil topical solution led to the greatest increase in hair density among Chinese men with androgenetic alopecia.

This study found that applying a growth factor cocktail including FGF9 with microneedling significantly increased hair density and diameter in patients with androgenetic alopecia, with similar results regardless of microneedle depths between 0.5 mm and 0.8 mm.

This study found that combining low-level light therapy with topical minoxidil 5% may lead to better hair regrowth and patient satisfaction in treating female pattern hair loss compared to using each treatment alone.

In this study, Korean women with female pattern hair loss who used a combination of topical 0.025% 17α-estradiol and 3% minoxidil saw significant increases in total hair count and hair caliber over six months.

This study found that a 0.5-mm microneedle depth was more effective than 0.3 mm for increasing hair density in AGA patients treated with a topical growth factor cocktail.

This study found that adding microneedling to minoxidil treatment significantly improved hair growth in men with androgenetic alopecia compared to minoxidil alone across all assessed measures.

This study found that 12 months of minoxidil treatment increased hair density and thickness in women with androgenetic alopecia, while alfatradiol primarily stabilized hair loss.

In this 48-week trial, 5% topical minoxidil was more effective than both 2% minoxidil and placebo in promoting hair growth in women with female pattern hair loss, with notable improvements in nonvellus hair count and hair growth assessments.

This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.

This study found that 1% and 2% topical minoxidil solutions resulted in clinically noticeable hair growth compared to lower doses or placebo in men with male pattern baldness.